EmboCept® S DSM 50 µm is certified for chemoembolization of inoperable liver and lung tumours (DSM-TACE).



EmboCept Case Study – Mets From Ovarian Cancer 

EmboCept Case Study – Transpulmonary Chemoembolization of NSCLC 

CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation

Material Amilomer (DSM* 35/50)
Half-Life 30-40 Minutes
Average Size of Microspheres 50 µm ± 7 ųm
Size Distribution of Microspheres Min 95% 20-90 µm // Max 4.0% > 90 µm // Max 2.5% > 20 µm
Indication Transarterial chemoembolization (TACE) of inoperable liver and lung tumours.
Dosage 2.5 – 7.5 ml (150 – 450 mg), depending on tumour size and vascularization, arterial blood flow and arteriovenous shunt volume. Maximum dose of 15 ml (900 mg) possible in individual cases.
Mechanism of Action Reduction of blood flow causes short term ischemia in addition to a local concentration increase of the simultaneously applied cytostatic agent.
Package Size 450 mg Amilomer in 7.5 ml saline solution.

Contact APC for more information on the full range of Interventional Oncology.